Skip to main content

Advertisement

SpringerLink
Log in

Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Increasing evidence supports the concept of macrophage migration inhibitory factor (MIF) as a central proinflammatory cytokine in autoimmune diseases. To further evaluate its role in systemic sclerosis (SSc), serum levels of MIF were determined by enzyme-linked immunoassay, and correlations to clinical manifestations were analyzed in 43 patients. MIF levels were significantly increased in patients (median, 18.8; range, <0.015–189 ng/ml) in comparison to healthy controls (n = 43, 8.0, <0.015–36.5 ng/ml; P < 0.0005). MIF values were higher in diffuse than in limited cutaneous SSc (P < 0.005). Patients with pulmonary hypertension and recurrent digital ulcers showed higher MIF levels than patients without these manifestations (P < 0.005). This association was also observed in limited cutaneous SSc. Sequential studies revealed decreased MIF levels after initiation of immunosuppressive therapy. MIF levels were not significantly different in patients with and without macrovascular disease of the peripheral arteries. The results suggest that MIF might contribute to inflammation and vasculopathy in SSc.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sakkas LI, Chikanza IC, Platsoucas CD (2006) Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2:679–685

    Article  PubMed  CAS  Google Scholar 

  2. Abraham DJ, Varga J (2005) Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26:587–595

    Article  PubMed  CAS  Google Scholar 

  3. Bacher M, Metz CN, Calandra T et al (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854

    Article  PubMed  CAS  Google Scholar 

  4. Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895–1902

    Article  PubMed  CAS  Google Scholar 

  5. Nishihira J, Koyama Y, Mizue Y (1998) Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 10:199–205

    Article  PubMed  CAS  Google Scholar 

  6. Gregersen PK, Bucala R (2003) Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 48:1771–1776

    Article  Google Scholar 

  7. Selvi E, Tripodi SA, Catenaccio M et al (2003) Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Ann Rheum Dis 62:460–464

    Article  PubMed  CAS  Google Scholar 

  8. Wu S-P, Leng L, Feng Z et al (2006) Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 54:3661–3669

    Article  PubMed  CAS  Google Scholar 

  9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

    Article  Google Scholar 

  10. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205

    PubMed  CAS  Google Scholar 

  11. Becker H, Maaser C, Mickholz E, Dyong A, Domschke W, Gaubitz M (2006) Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides. Clin Rheumatol 25:368–372

    Article  PubMed  Google Scholar 

  12. Kahaleh MB (2004) Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 16:718–722

    Article  PubMed  Google Scholar 

  13. Amin MA, Haas CS, Zhu K et al (2006) Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood 107:2252–2261

    Article  PubMed  CAS  Google Scholar 

  14. Mukerjee D, Jap LB, Ong V et al (2004) The myth of pulmonary Raynaud’s phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension. Ann Rheum Dis 63:1627–1631

    Article  PubMed  CAS  Google Scholar 

  15. Trad S, Amoura Z, Beigelman C et al (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54:184–191

    Article  PubMed  Google Scholar 

  16. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Du Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239–243

    Article  PubMed  CAS  Google Scholar 

  17. Ho M, Veale D, Eastmond C, Nuki G, Belch J (2000) Macrovascular disease and systemic sclerosis. Ann Rheum Dis 59:39–43

    Article  PubMed  CAS  Google Scholar 

  18. Ayoub S, Hickey MJ, Morand EF (2008) Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Clin Prac Rheumatol 4:98–105

    Article  CAS  Google Scholar 

  19. Szucs G, Tímár O, Szekanecz Z et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatology (Oxford) 46:759–762

    Article  CAS  Google Scholar 

  20. Scala E, Pallotta S, Frezzolini A et al (2004) Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138:540–546

    Article  PubMed  CAS  Google Scholar 

  21. Calandra T, Bernhagen J, Metz CN et al (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68–71

    Article  PubMed  CAS  Google Scholar 

  22. Wheelhouse NM, Dowidar N, Dejong CH et al (2006) The effects of macrophage migration inhibitory factor on acute-phase protein production in primary human hepatocytes. Int J Mol Med 18:957–961

    PubMed  CAS  Google Scholar 

  23. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275–284

    PubMed  CAS  Google Scholar 

  24. Stavitsky AB, Xianli J (2002) In vitro and in vivo regulation of macrophage migration inhibitory factor (MIF) of expression of MHC-II, costimulatory, adhesion, receptor, and cytokine molecules. Cell Immunol 217:95–104

    Article  PubMed  CAS  Google Scholar 

  25. Sato S, Hanakawa H, Hasegawa M et al (2000) Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 27:2838–2842

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

We thank Eva Mickholz for excellent technical assistance.

Conflict of interest statement

No disclosures.

Author information

Authors and Affiliations

  1. Department of Medicine B, University of Muenster, Albert-Schweitzer-Str. 33, 48129, Muenster, Germany

    Heidemarie Becker, Peter Willeke, Heiko Schotte, Wolfram Domschke & Markus Gaubitz

Authors
  1. Heidemarie Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Willeke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heiko Schotte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wolfram Domschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Markus Gaubitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heidemarie Becker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Becker, H., Willeke, P., Schotte, H. et al. Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis. Clin Rheumatol 27, 1307–1311 (2008). https://doi.org/10.1007/s10067-008-0960-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-008-0960-7

Keywords

Search

Navigation